We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Benign Hematology

Journal Scan / Research · February 18, 2021

Renal Response Better With Carfilzomib vs Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Blood advances

 

Additional Info

Blood advances
Renal Response in Real-World Carfilzomib- vs Bortezomib-Treated Patients With Relapsed or Refractory Multiple Myeloma
Blood Adv 2021 Jan 26;5(2)367-376, S Kumar, A Fu, R Niesvizky, S Jagannath, R Boccia, N Raje

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading